Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart

If history is any guide, there may be trouble ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

What To Know: Many traders use moving average crossover systems to make their decisions.

When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term average price, it means the trend is lower.

Why It's Important: The 50-day and the 200-day simple moving averages are commonly used.

The death cross occurs when the 50-day moves below the 200-day. This could mean the long-term trend is changing.

That just happened with Alnylam Pharmaceuticals, which is trading around $136.21 at publication time.

Remember: Seasoned investors don't blindly trade Death Crosses.

Instead, they use it as a signal to start looking for short positions based on other factors, like price levels and company fundamentals & events.

For seasoned investors, this is just a sign that it might be time to start considering possible short positions.

With that in mind, take a look at Alnylam Pharmaceuticals's past and upcoming earnings expectations:

Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate -1.57 -1.6 -1.75 -1.76
EPS Actual -1.51 -1.3 -1.64 -1.60
Revenue Estimate 218.69M 193.18M 168.74M 146.07M
Revenue Actual 187.63M 220.55M 177.57M 163.56M

Also consider this overview of Alnylam Pharmaceuticals analyst ratings:

Do you use the Death Cross signal in your trading or investing? Share this article with a friend if you found it helpful!

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.